Evan T. Keller, DVM, PhD is a Professor of Urology and Pathology, School of Medicine, University of Michigan. He is Associate Director for Shared Resource for the University of Michigan Comprehensive Rogel Cancer Center; Directs an NIH-funded Program Project on Prostate Cancer Bone Metastasis; Director of the Single Cell Spatial Analysis Program; and Co-Director of the Single Cell Analysis Core. Dr. Keller obtained Doctor of Veterinary Medicine (DVM) and Master of Preventive Veterinary Medicine (MPVM) degrees at University of California and attained American College of Veterinary Internal Medicine certification in Oncology and a PhD in Developmental Biology at the University of Wisconsin, Madison. His areas of research include (1) prostate cancer metastasis research, with a special emphasis on bone metastasis and the tumor microenvironment and (2) single cell analytic methods. He is the principal investigator on numerous NIH, DOD and pharmaceutical-funded studies. Dr. Keller has over 200 publications to date in areas such as aging, cytokines, bone metastasis and prostate cancer biology. He is Editor of a book on “The Biology of Skeletal Metastases.” He sits on several foundations, NIH and Department of Defense peer review panels and sits on several Editorial boards. He has consulted for many companies including Lilly, Parke-Davis, Pfizer, Centocor, Immunex, Amgen, Novartis, Merck and Eisai Pharmaceuticals. Key research accomplishments include (1) defining importance of osteoclastic activity and targeting it in prostate cancer leading to clinical use of RANKL inhibitor (Denosumab); (2) identification of raf kinase inhibitor protein (RKIP) as a novel metastasis suppressor gene; (3) determining the importance of the Wnt pathway in bone metastasis; and (4) defining interleukin-6 as a contributor to castration resistant prostate cancer.
(1) prostate cancer metastasis research, with a special emphasis on bone metastasis and the tumor microenvironment
(2) single cell analytic methods.